Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome–associated glioma

Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome–associated glioma

Germline replication-repair deficient (gRRD) gliomas are exceptional events, and only a few of them have been treated with immune checkpoint inhibitors (ICIs). Contrary to sporadic gliomas, where ICIs have failed to show any objective benefit, the very few patients with gRRD gliomas treated with ICI...

Full description

Bibliographic Details
Main Authors: Santiago Cabezas-Camarero, Rebeca Pérez-Alfayate, Vanesa García-Barberán, María Carmen Polidura, María Natividad Gómez-Ruiz, Isabel Casado-Fariñas, Issa Ahmad Subhi-Issa, José Carlos Plaza Hernández, Pilar Garre, Isabel Díaz-Millán, Pedro Pérez-Segura
Format: Article
Language:English
Published: SAGE Publishing 2022-05-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359221100863

Internet

https://doi.org/10.1177/17588359221100863

Similar Items